Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Deputy Asia Editor
India
21+ years of experience
Anju has extensive experience at India's mainstream financial dailies, The Economic Times, The Hindu Business Line and The Financial Express. As Corporate Bureau Chief (Mumbai), she led a team of reporters at The Financial Express prior to joining Scrip. She’s been associated with Scrip since 2001, when it was part of PJB Publications.
Anju enjoys covering pharma conferences and interviewing industry heads and regulatory/government officials in the region. Occasionally, she also moderates industry panels at key events.
She follows racket sports closely and has previously received recognition at the national level in India. She loves the hills and when not reporting on pharma believes that nature is the best therapy.
Scrip
By Anju Ghangurde 27 Sep 2021
Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in healthcare and how life science companies can adapt from them while leveraging core capabilities at scale.
Scrip
By Anju Ghangurde 03 Aug 2021
Glenmark hopes to launch SaNOtize’s nitric oxide nasal spray for COVID-19 in India by the fourth quarter of 2021 post Phase III trials, as part of wider deal that covers other Asian markets. Can the self-administered product impact market dynamics positioned as the first line of defense against COVID-19?
Generics Bulletin
By Anju Ghangurde 30 Jul 2021
Dr Reddy’s is to press ahead with India filing plans for single-dose COVID-19 vaccine Sputnik Light and also expects to “build on” the Russian partner’s trial in adolescents of the two-dose Sputnik V. The company also pilots a partnered first-of-its-kind cashless digital health offering.
Scrip
By Anju Ghangurde 07 Jul 2021
The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.
Scrip
By Anju Ghangurde 30 Jun 2021
SaNOtize is to start Phase III trials for its nitric oxide nasal spray for COVID-19 and hopes to enlist volunteers from several countries, including India. The Canadian firm claims initial studies have demonstrated effectiveness across SARS-CoV-2 mutations, with plans afoot to validate it against the spreading Delta variant.
Scrip
By Anju Ghangurde 07 Jun 2021
In this audio interview, the head of IQVIA Biotech (Japan-Asia Pacific) talks to Scrip on a range of aspects around digitalization and virtualization of clinical research in the region, including sharply reduced site contracting timelines. He also touches on the digital product launch efforts that are currently a reality in several markets.
In Vivo
By Anju Ghangurde 16 Mar 2021
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.
Scrip
By Anju Ghangurde 08 Dec 2020
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
Topic Coronavirus Vaccines Distribution
Generics Bulletin
By Anju Ghangurde 27 Nov 2020
Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.
Topic Coronavirus Drug Review
Generics Bulletin
By Anju Ghangurde 27 Nov 2020
Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.
Scrip
By Anju Ghangurde 28 Oct 2020
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up
Topic Vaccines Coronavirus
Scrip
By Anju Ghangurde 21 Sep 2020
Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.
Topic Coronavirus Vaccines
Scrip
By Anju Ghangurde 22 Apr 2020
The coronavirus pandemic could dull pharma M&A activity in the short-term as companies hoard cash and prioritize core activities. But experts say stress in the system could potentially push some firms to cull surplus assets or seek financial/strategic investors, amid a generally tough funding environment. Private equity investors may also find attractive investment opportunities to pursue.
Topic Coronavirus
Scrip
By Anju Ghangurde 14 Apr 2020
Parexel executives tell Scrip about the company’s efforts in tandem with sponsors to navigate the challenging clinical research environment amid COVID-19. A renewed interest for decentralized trials or hybrid approaches and the use of remote monitoring and telehealth visits to keep studies moving are some of the key initiatives.
Topic Coronavirus
Scrip
By Anju Ghangurde 27 Mar 2020
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
Topic Coronavirus
Pink Sheet
14 Jul 2022
Pink Sheet
07 Jul 2022
Generics Bulletin
04 Jul 2022
Scrip
23 Jun 2022
Pink Sheet
21 Jun 2022
Scrip
20 Jun 2022
Generics Bulletin
16 Jun 2022
Scrip
16 Jun 2022
Generics Bulletin
15 Jun 2022
Scrip
13 Jun 2022
HBW Insight
08 Jun 2022
Scrip
27 May 2022
Scrip
23 May 2022
Generics Bulletin
17 May 2022
Generics Bulletin
06 May 2022
